Search

Your search keyword '"Otten, Hans-Martin"' showing total 182 results
Start Over Author "Otten, Hans-Martin"
182 results on '"Otten, Hans-Martin"'

1. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study

Author

van der Kleij, Maud B. A., Guchelaar, Niels A. D., Meertens, Marinda, Westerdijk, Kim, Giraud, Eline L., Bleckman, Roos F., Groenland, Stefanie L., van Eerden, Ruben A. G., Imholz, Alex L. T., Vulink, Annelie J. E., Otten, Hans-Martin, Fiebrich-Westra, Helle-Brit, Lubberman, Floor J. E., Desar, Ingrid M. E., Moes, Dirk-Jan A. R., Touw, Daan J., Koolen, Stijn L. W., Gelderblom, Hans, Reyners, An K. L., van Erp, Nielka P., Mathijssen, Ron H. J., Huitema, Alwin D. R., and Steeghs, Neeltje

Published
2024
Full Text
View/download PDF

2. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort

Author

Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B. A., Westerdijk, Kim, Guchelaar, Niels A. D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L. T, Otten, Hans-Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T. A., Gelderblom, Hans, Moes, Dirk Jan A. R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L. W., Mathijssen, Ron H. J., Huitema, Alwin D. R., van Erp, Nielka P., Desar, Ingrid M. E., and Steeghs, Neeltje

Published
2024
Full Text
View/download PDF

5. Platelet RNA sequencing for cancer screening in patients with unprovoked venous thromboembolism: a prospective cohort study

Author

Mulder, Frits I., Kraaijpoel, Noémie, Carrier, Marc, Guman, Noori A., Jara-Palomares, Luis, Di Nisio, Marcello, Ageno, Walter, Beyer-Westendorf, Jan, Klok, Frederikus A., Vanassche, Thomas, Otten, Hans-Martin B., Cosmi, Benilde, Wolde, Marije ten, In ‘t Veld, Sjors G.J. G., Post, Edward, Ramaker, Jip, Zwaan, Kenn, Peters, Mike, Delluc, Aurélien, Kamphuisen, Pieter W., Sanchez-Lopez, Veronica, Porreca, Ettore, Bossuyt, Patrick M.M., Büller, Harry R., Wurdinger, Thomas, Best, Myron G., and van Es, Nick

Published
2023
Full Text
View/download PDF

7. Experiences of patients with metastatic colorectal cancer participating in a supervised exercise intervention during chemotherapy.

Author

Brouwer, Calvin G., Tusscher, Marieke R. ten, de Roos, Bente M., Gootjes, Elske C., Buffart, Tineke E., Versteeg, Kathelijn S., Mast, Isa H., Streppel, Mirte M., Werter, Inge M., May, Anne M., Verheul, Henk M. W., Buffart, Laurien M., Roodhart, Jeanine M. L., Wumkes, Miriam L., Sommeijer, Dirkje W., Creemers, Geert-Jan, Otten, Hans-Martin M. B., van Zweeden, Annette, Beeker, Aart, and Janssen, Johan J. B.

Abstract

Purpose: Patients with metastatic colorectal cancer (mCRC) undergoing systemic treatment often experience toxicities. Although exercise may improve physical fitness and quality of life and counteract treatment toxicity, knowledge in patients with mCRC is limited. The ongoing randomized controlled AMICO trial evaluates the effects of supervised exercise on clinical outcomes. The present qualitative study was a pre-planned part of this trial aiming to capture adherence, satisfaction, and perceived effects of exercise among patients with mCRC. Methods: Patients with mCRC receiving first-line systemic treatment were randomized (1:1:1) to a control group or one of two supervised exercise arms including continuous aerobic exercise with either resistance exercises or high-intensity interval training. Semi-structured interviews with patients in the exercise arms were transcribed verbatim and thematically analyzed. Descriptive data on adherence (exercise logs) and satisfaction (questionnaire) was collected to complement and contextualize the qualitative findings. Results: Twenty-one patients were interviewed. Median exercise attendance was 67% [IQR 35–91], and the median satisfaction score was 8 [IQR 8–9] out of 10. Patients valued the guidance and knowledge of the physical therapist and expressed interindividual preferences regarding training content. Patients experienced that exercise improved their physical and mental wellbeing and helped them to endure treatment. Perceived exercise barriers were treatment toxicity, physical problems, and hospital appointments. Perceived exercise facilitators included adequate tailoring and internal or external motivation. Conclusion: Patients with mCRC appreciated exercise during systemic treatment and perceived several beneficial effects, both physically and mentally. Exercise attendance varied and barriers were mainly treatment- and disease-related. Trial registration: Clinical trial.GOV ID: NCT04754672. Date of registration: 04–12-2020. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

8. Novel biomarkers to detect occult cancer in patients with unprovoked venous thromboembolism: Rationale and design of the PLATO-VTE study

Author

Kraaijpoel, Noémie, Mulder, Frits I., Carrier, Marc, van Lieshout, Annabel, Würdinger, Tom, Best, Myron G., van Vlijmen, Bart J.M., Mohammed, Yassene, Jara-Palomares, Luis, Kamphuisen, Pieter W., Di Nisio, Marcello, Ageno, Walter, Beyer-Westendorf, Jan, Vanassche, Thomas, Klokm, Frederikus A., Otten, Hans-Martin, Peters, Mike J.L., Cosmi, Benilde, Wolde, Marije ten, Bossuyt, Patrick M.M., Büller, Harry R., and van Es, Nick

Published
2021
Full Text
View/download PDF

10. Improving sustainability of a patient decision aid for systemic treatment of metastatic colorectal cancer: A qualitative study

Author

Medisch Oncologische Disciplines, Onderzoek Medische Oncologie, Cancer, Global Health, MS Medische Oncologie, JC onderzoeksprogramma Kanker, van Nassau, Sietske C.M.W., Voogdt-Pruis, Helene R., de Jong, Vincent M.W., Otten, Hans Martin, Valkenburg-van Iersel, Liselot B., Swarte, Bas J., Buffart, Tineke E., Pruijt, Hans J., Mekenkamp, Leonie J., Koopman, Miriam, May, Anne M., Medisch Oncologische Disciplines, Onderzoek Medische Oncologie, Cancer, Global Health, MS Medische Oncologie, JC onderzoeksprogramma Kanker, van Nassau, Sietske C.M.W., Voogdt-Pruis, Helene R., de Jong, Vincent M.W., Otten, Hans Martin, Valkenburg-van Iersel, Liselot B., Swarte, Bas J., Buffart, Tineke E., Pruijt, Hans J., Mekenkamp, Leonie J., Koopman, Miriam, and May, Anne M.

Published
2024

11. Evaluating the Clinical Impact and Feasibility of Therapeutic Drug Monitoring of Pazopanib in a Real-World Soft-Tissue Sarcoma Cohort

Author

Apotheek O&O&O, Cancer, Medisch Oncologische Disciplines, MS Medische Oncologie, Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B.A., Westerdijk, Kim, Guchelaar, Niels A.D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L.T., Otten, Hans Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T.A., Gelderblom, Hans, Moes, Dirk Jan A.R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L.W., Mathijssen, Ron H.J., Huitema, Alwin D.R., van Erp, Nielka P., Desar, Ingrid M.E., Steeghs, Neeltje, the Dutch Pharmacology Oncology Group (DPOG), Apotheek O&O&O, Cancer, Medisch Oncologische Disciplines, MS Medische Oncologie, Meertens, Marinda, Giraud, Eline L., van der Kleij, Maud B.A., Westerdijk, Kim, Guchelaar, Niels A.D., Bleckman, Roos F., Rieborn, Amy, Imholz, Alex L.T., Otten, Hans Martin, Vulink, Annelie, Los, Maartje, Hamberg, Paul, van der Graaf, Winette T.A., Gelderblom, Hans, Moes, Dirk Jan A.R., Broekman, K. Esther, Touw, Daan J., Koolen, Stijn L.W., Mathijssen, Ron H.J., Huitema, Alwin D.R., van Erp, Nielka P., Desar, Ingrid M.E., Steeghs, Neeltje, and the Dutch Pharmacology Oncology Group (DPOG)

Published
2024

12. Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology - an analysis of the closed cohorts of a multicentre prospective study

Author

Apotheek O&O&O, Cancer, MS Medische Oncologie, van der Kleij, Maud B A, Guchelaar, Niels A D, Meertens, Marinda, Westerdijk, Kim, Giraud, Eline L, Bleckman, Roos F, Groenland, Stefanie L, van Eerden, Ruben A G, Imholz, Alex L T, Vulink, Annelie J E, Otten, Hans-Martin, Fiebrich-Westra, Helle-Brit, Lubberman, Floor J E, Desar, Ingrid M E, Moes, Dirk-Jan A R, Touw, Daan J, Koolen, Stijn L W, Gelderblom, Hans, Reyners, An K L, van Erp, Nielka P, Mathijssen, Ron H J, Huitema, Alwin D R, Steeghs, Neeltje, Dutch Pharmacology Oncology Group (DPOG), Apotheek O&O&O, Cancer, MS Medische Oncologie, van der Kleij, Maud B A, Guchelaar, Niels A D, Meertens, Marinda, Westerdijk, Kim, Giraud, Eline L, Bleckman, Roos F, Groenland, Stefanie L, van Eerden, Ruben A G, Imholz, Alex L T, Vulink, Annelie J E, Otten, Hans-Martin, Fiebrich-Westra, Helle-Brit, Lubberman, Floor J E, Desar, Ingrid M E, Moes, Dirk-Jan A R, Touw, Daan J, Koolen, Stijn L W, Gelderblom, Hans, Reyners, An K L, van Erp, Nielka P, Mathijssen, Ron H J, Huitema, Alwin D R, Steeghs, Neeltje, and Dutch Pharmacology Oncology Group (DPOG)

Published
2024

13. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis

Author

Amin, Elham E, ten Cate-Hoek, Arina J, Bouman, Annemieke C, Meijer, Karina, Tick, Lidwine, Middeldorp, Saskia, Mostard, Guy, ten Wolde, Marije, van den Heiligenberg, Simone, van Wissen, Sanne, van de Poel, Marlene, Villalta, Sabina, Serné, Erik, Otten, Hans Martin, Klappe, Edith, Prandoni, Paolo, Prins, Martin H, ten Cate, Hugo, and Joore, Manuela A

Published
2018
Full Text
View/download PDF

17. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial

Author

ten Cate-Hoek, Arina J, ten Cate, Hugo, Joore, Manuela A, Prins, Martin H, Amin, Elham E, Bouman, Annemieke C, Meijer, Karina, Piersma-Wichers, Margriet, Tick, Lidwine W, Nijziel, Martin R, Middeldorp, Saskia, Lauw, Mandy, Cheung, Y Whitney, Mostard, Guy J M, ten Wolde, Marije, Bistervels, Ingrid M, van den Heiligenberg, Simone M, van Wissen, Sanne, van de Poel, Marlène H W, Otten, Hans-Martin, Serné, Erik H, Klappe, Edith H, Prandoni, Paolo, Vedovetto, Valentina, Villalta, Sabina, van de Poel, Marlène HW, and Lauw, Mandy N

Published
2018
Full Text
View/download PDF

23. Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, d-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis: A Prospective Management Study

Author

Kleinjan, Ankie, Di Nisio, Marcello, Beyer-Westendorf, Jan, Camporese, Giuseppe, Cosmi, Benilde, Ghirarduzzi, Angelo, Kamphuisen, Pieter W., Otten, Hans-Martin, Porreca, Ettore, Aggarwal, Anita, Brodmann, Marianne, Guglielmi, Maria Domenica, Iotti, Matteo, Kaasjager, Karin, Kamvissi, Virginia, Lerede, Teresa, Marschang, Peter, Meijer, Karina, Palareti, Gualtiero, Rickles, Frederick R., Righini, Marc, Rutjes, Anne W.S., Tonello, Chiara, Verhamme, Peter, Werth, Sebastian, van Wissen, Sanne, and Büller, Harry R.

Published
2014

34. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

Author

Crombag, Marie-Rose B S, de Vries Schultink, Aurelia H M, van Doremalen, Jacobine G C, Otten, Hans-Martin, Bergman, Andries M, Schellens, Jan H M, Beijnen, Jos H, Huitema, Alwin D R, Crombag, Marie-Rose B S, de Vries Schultink, Aurelia H M, van Doremalen, Jacobine G C, Otten, Hans-Martin, Bergman, Andries M, Schellens, Jan H M, Beijnen, Jos H, and Huitema, Alwin D R

Abstract

BACKGROUND: Older patients with metastatic castration-resistant prostate cancer (mCRPC) may be more prone to chemotherapy-induced hematological toxicity, but tailored docetaxel dosing guidelines in older patients are lacking because of conflicting data.OBJECTIVE: This study aims to evaluate the impact of older age on the incidence of hematological toxicity in patients with mCRPC treated with docetaxel in daily clinical practice.METHODS: This study included patients with mCRPC treated with docetaxel between January 2006 and January 2016 at the Netherlands Cancer Institute and Medical Center Slotervaart for whom dosing and hematological toxicity data were available from electronic patient records. We evaluated the impact of age on the incidence of grade 3 and 4 hematological toxicity.RESULTS: In total, 175 patients treated with docetaxel were included in the analysis, with a median age of 67 years (range 47-86). Baseline hematological laboratory values were not age related. After the first treatment cycle, hematological toxicity occurred significantly more frequently in the oldest age quartile (25%, p = 0.02) than in the younger age quartiles (9%, 11%, and 7%, respectively, for age quartiles 1, 2, and 3).CONCLUSION: The risk of hematological toxicity was significantly higher in the oldest age quartile than in younger patients with mCRPC treated with docetaxel in daily clinical practice.

Published
2019

35. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort

Author

de Vries Schultink, Aurelia H M, Crombag, Marie-Rose B S, van Werkhoven, Erik, Otten, Hans-Martin, Bergman, Andre M, Schellens, Jan H M, Huitema, Alwin D R, Beijnen, Jos H, de Vries Schultink, Aurelia H M, Crombag, Marie-Rose B S, van Werkhoven, Erik, Otten, Hans-Martin, Bergman, Andre M, Schellens, Jan H M, Huitema, Alwin D R, and Beijnen, Jos H

Abstract

The incidence of neutropenia in metastatic castration-resistant prostate cancer (mCRPC) patients treated with docetaxel has been reported to be lower compared to patients with other solid tumors treated with a similar dose. It is suggested that this is due to increased clearance of docetaxel in mCRPC patients, resulting in decreased exposure. The aims of this study were to (1) determine if exposure in mCRPC patients is lower vs patients with other solid tumors by conducting a meta-analysis, (2) evaluate the incidence of neutropenia in patients with mCRPC vs other solid tumors in a clinical cohort, and (3) discuss potential clinical consequences. A meta-analysis was conducted of studies which reported areas under the plasma concentration-time curves (AUCs) of docetaxel and variability. In addition, grade 3/4 neutropenia was evaluated using logistic regression in a cohort of patients treated with docetaxel. The meta-analysis included 36 cohorts from 26 trials (n = 1150 patients), and showed that patients with mCRPC had a significantly lower mean AUC vs patients with other solid tumors (fold change [95% confidence interval (CI)]: 1.8 [1.5-2.2]), with corresponding AUCs of 1.82 and 3.30 mg∙h/L, respectively. Logistic regression, including 812 patient, demonstrated that patients with mCRPC had a 2.2-fold lower odds of developing grade 3/4 neutropenia compared to patients with other solid tumors (odds ratio [95%CI]: 0.46 [0.31-0.90]). These findings indicate that mCRPC patients have a lower risk of experiencing severe neutropenia, possibly attributable to lower systemic exposure to docetaxel.

Published
2019

36. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

Author

Crombag, Marie Rose B.S., de Vries Schultink, Aurelia H.M., van Doremalen, Jacobine G.C., Otten, Hans Martin, Bergman, Andries M., Schellens, Jan H.M., Beijnen, Jos H., Huitema, Alwin D.R., Crombag, Marie Rose B.S., de Vries Schultink, Aurelia H.M., van Doremalen, Jacobine G.C., Otten, Hans Martin, Bergman, Andries M., Schellens, Jan H.M., Beijnen, Jos H., and Huitema, Alwin D.R.

Published
2019

37. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Vries Schultink, Aurelia H M, Crombag, Marie-Rose B S, van Werkhoven, Erik, Otten, Hans-Martin, Bergman, Andre M, Schellens, Jan H M, Huitema, Alwin D R, Beijnen, Jos H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, de Vries Schultink, Aurelia H M, Crombag, Marie-Rose B S, van Werkhoven, Erik, Otten, Hans-Martin, Bergman, Andre M, Schellens, Jan H M, Huitema, Alwin D R, and Beijnen, Jos H

Published
2019

38. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Crombag, Marie-Rose B S, de Vries Schultink, Aurelia H M, van Doremalen, Jacobine G C, Otten, Hans-Martin, Bergman, Andries M, Schellens, Jan H M, Beijnen, Jos H, Huitema, Alwin D R, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Crombag, Marie-Rose B S, de Vries Schultink, Aurelia H M, van Doremalen, Jacobine G C, Otten, Hans-Martin, Bergman, Andries M, Schellens, Jan H M, Beijnen, Jos H, and Huitema, Alwin D R

Published
2019

39. Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort

Author

Cancer, Apotheek Onderzoek, de Vries Schultink, Aurelia H M, Crombag, Marie-Rose B S, van Werkhoven, Erik, Otten, Hans-Martin, Bergman, Andre M, Schellens, Jan H M, Huitema, Alwin D R, Beijnen, Jos H, Cancer, Apotheek Onderzoek, de Vries Schultink, Aurelia H M, Crombag, Marie-Rose B S, van Werkhoven, Erik, Otten, Hans-Martin, Bergman, Andre M, Schellens, Jan H M, Huitema, Alwin D R, and Beijnen, Jos H

Published
2019

40. Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

Author

UMC Utrecht, Apotheek Onderzoek, Crombag, Marie Rose B.S., de Vries Schultink, Aurelia H.M., van Doremalen, Jacobine G.C., Otten, Hans Martin, Bergman, Andries M., Schellens, Jan H.M., Beijnen, Jos H., Huitema, Alwin D.R., UMC Utrecht, Apotheek Onderzoek, Crombag, Marie Rose B.S., de Vries Schultink, Aurelia H.M., van Doremalen, Jacobine G.C., Otten, Hans Martin, Bergman, Andries M., Schellens, Jan H.M., Beijnen, Jos H., and Huitema, Alwin D.R.

Published
2019

41. Relationship between type of unprovoked venous thromboembolism and cancer location: An individual patient data meta-analysis

Author

Jara Palomares, Luis, van Es, Nick, Praena-Fernández, Juan Manuel, Le Gal, Grégoire, Otten, Hans-Martin, Robin, Philippe, Piccioli, Andrea, Lécumberri, Ramon, Religa, Piotr, Rieu, Viriginie, Rondina, Matthew T., Beckers, P. M., Prandoni, Paolo, Salaun, Pierre-Yves, Di Nisio, Marcello, Bossuyt, Patrick M., Kraaijpoelc, K., Büller, Harry R., Carrier, Marc, Jara Palomares, Luis, van Es, Nick, Praena-Fernández, Juan Manuel, Le Gal, Grégoire, Otten, Hans-Martin, Robin, Philippe, Piccioli, Andrea, Lécumberri, Ramon, Religa, Piotr, Rieu, Viriginie, Rondina, Matthew T., Beckers, P. M., Prandoni, Paolo, Salaun, Pierre-Yves, Di Nisio, Marcello, Bossuyt, Patrick M., Kraaijpoelc, K., Büller, Harry R., and Carrier, Marc

Abstract

[Background] Unprovoked venous thromboembolism (VTE) may be the first manifestation of an underlying cancer. We aimed to assess the period prevalence of occult cancer detection stratified by VTE location (deep vein thrombosis [DVT], pulmonary embolism [PE] or both) and the anatomical relationship between occult cancer and VTE., [Methods] Post-hoc analysis of a systematic review and individual patient data meta-analysis of adults with unprovoked VTE with at least 12 months of follow-up. Cancer types were grouped according to thoracic, abdomino-pelvic, or other locations., [Results] A total of 2300 patients were eligible including 1218 with DVT only (53%), 719 with PE only (31%), and 363 with both PE and DVT (16%). The pooled 12-month period prevalence of cancer in DVT only, PE only, and DVT + PE was 5.6% (95% CI, 4.4 to 7.2), 4.3% (95% CI, 2.7 to 6.9), and 5.6% (95% CI, 1.7 to 15.5), respectively. Most occult cancers were located in the abdomen (68.4%). The proportion of patients with an abdomino-pelvic cancer was not different in patients with DVT + PE (81%; 95% CI, 54 to 96) than in those with DVT (68%; 95% CI, 57 to 78) or PE alone (65%; 95% CI, 48 to 79)., [Conclusion] The 12-month prevalence of occult cancer was similar in patients with DVT only, PE only, or both. Most cancers were located in the abdomen, and there was no relationship between VTE type and cancer location.

Published
2019

43. Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial

Author

ten Cate-Hoek, Arina J., ten Cate-Hoek, Arina J., Amin, Elham E., Bouman, Annemieke C., Meijer, Karina, Tick, Lidwine W., Middeldorp, Saskia, Mostard, Guy J. M., ten Wolde, Marije, van den Heiligenberg, Simone M., van Wissen, Sanne, van de Poel, Marlene H. W., Villalta, Sabina, Serne, Erik H., Otten, Hans-Martin, Klappe, Edith H., Bistervels, Ingrid M., Lauw, Mandy N., Piersma-Wichers, Margriet, Prandoni, Paolo, Joore, Manuela A., Prins, Martin H., ten Cate, Hugo, IDEAL DVT Investigators, ten Cate-Hoek, Arina J., ten Cate-Hoek, Arina J., Amin, Elham E., Bouman, Annemieke C., Meijer, Karina, Tick, Lidwine W., Middeldorp, Saskia, Mostard, Guy J. M., ten Wolde, Marije, van den Heiligenberg, Simone M., van Wissen, Sanne, van de Poel, Marlene H. W., Villalta, Sabina, Serne, Erik H., Otten, Hans-Martin, Klappe, Edith H., Bistervels, Ingrid M., Lauw, Mandy N., Piersma-Wichers, Margriet, Prandoni, Paolo, Joore, Manuela A., Prins, Martin H., ten Cate, Hugo, and IDEAL DVT Investigators

Abstract

Background Therapy with elastic compression stockings has been the cornerstone for prevention of post-thrombotic syndrome for decades in patients after acute deep venous thrombosis. It is uncertain who benefits most from therapy, and what the optimum duration of therapy should be. We therefore aimed to assess the safety and efficacy of individualised duration of compression therapy versus the standard duration of 24 months following an initial treatment period of 6 months. Methods We did a multicentre, randomised, single-blind, allocation-concealed, non-inferiority trial at 12 hospitals in the Netherlands and two in Italy. We randomly assigned patients (1:1) with acute proximal deep vein thrombosis of the leg and without pre-existent venous insufficiency (Clinical Etiological Anatomical and Pathophysiological score

Published
2018

44. Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis

Author

Amin, Elham E., Amin, Elham E., ten Cate-Hoek, Arina J., Bouman, Annemieke C., Meijer, Karina, Tick, Lidwine, Middeldorp, Saskia, Mostard, Guy, ten Wolde, Marije, van den Heiligenberg, Simone, van Wissen, Sanne, van de Poet, Marlene, Villalta, Sabina, Serne, Erik, Otten, Hans Martin, Klappe, Edith, Prandoni, Paolo, Prins, Martin H., ten Cate, Hugo, Joore, Manuela A., Amin, Elham E., Amin, Elham E., ten Cate-Hoek, Arina J., Bouman, Annemieke C., Meijer, Karina, Tick, Lidwine, Middeldorp, Saskia, Mostard, Guy, ten Wolde, Marije, van den Heiligenberg, Simone, van Wissen, Sanne, van de Poet, Marlene, Villalta, Sabina, Serne, Erik, Otten, Hans Martin, Klappe, Edith, Prandoni, Paolo, Prins, Martin H., ten Cate, Hugo, and Joore, Manuela A.

Abstract

Background The IDEAL DVT study showed that it was safe to shorten the duration of elastic compression therapy on an individualised basis after deep vein thrombosis for prevention of post-thrombotic syndrome. In this study, we assessed the cost-effectiveness of this strategy.Methods IDEAL DVT was a multicentre, randomised, non-inferiority trial that included patients with acute proximal deep vein thrombosis of the leg. After 6 months of elastic compression therapy, patients were randomly assigned (1: 1) to the standard 2 years of elastic stocking compression therapy or shortened duration of compression therapy based on the patient's Villalta score. For our cost-effectiveness analysis, we assessed quality-adjusted life-years (QALYs), measured with the three-level version of EQ-5D (EQ-5D-3L; Dutch and UK tariff) and the 36-item Short Form Health Survey (SF-36), and costs in (SIC) (health-care and societal perspective) according to the intention-to-treat approach. Data were collected at 3, 6, 12, and 24 months after diagnosis of thrombosis. We calculated incremental net monetary benefit using a QALY threshold of (SIC) 30 000, and obtained bootstrapped means and 95% CIs. IDEAL DVT is registered with ClinicalTrials.gov, number NCT01429714.Findings Between March 22, 2011, and July 1, 2015, 865 patients were enrolled in IDEAL DVT. 437 were assigned to individualised duration of elastic compression therapy and 428 to standard duration of elastic compression therapy. Nine patients were eventually excluded because of recurrent venous thromboembolism within 6 months after the first event. From a societal perspective, for every QALY lost measured with the EQ-5D Dutch tariff, cost savings were (SIC) 305 center dot 992 (incremental net monetary benefit (SIC) 3205, 95% CI 502-5741), and for every QALY lost based on the Short-Form Six-Dimension (SF-6D) utility score (derived from SF-36), cost savings were (SIC) 6030.941 ((SIC) 3540, 95% CI 1174-5953). Using the UK t

Published
2018

45. Screening for Occult Cancer in Patients With Unprovoked Venous Thromboembolism

Author

van Es, Nick, primary, Le Gal, Grégoire, additional, Otten, Hans-Martin, additional, Robin, Philippe, additional, Piccioli, Andrea, additional, Lecumberri, Ramón, additional, Jara-Palomares, Luis, additional, Religa, Piotr, additional, Rieu, Virginie, additional, Rondina, Matthew, additional, Beckers, Mariëlle M., additional, Prandoni, Paolo, additional, Salaun, Pierre-Yves, additional, Di Nisio, Marcello, additional, Bossuyt, Patrick M., additional, Büller, Harry R., additional, and Carrier, Marc, additional

Published
2017
Full Text
View/download PDF

46. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis

Author

van Es, Nick, primary, Gal, Grégoire Le, additional, Otten, Hans-Martin, additional, Robin, Philippe, additional, Piccioli, Andrea, additional, Lécumberri, Ramon, additional, Palomares, Luis Jara, additional, Religa, Piotr, additional, Rieu, Viriginie, additional, Rondina, Matthew T., additional, Beckers, Mariëlle M, additional, Prandoni, Paolo, additional, Salaun, Pierre-Yves, additional, Nisio, Marcello Di, additional, Bossuyt, Patrick M, additional, Büller, Harry R, additional, and Carrier, Marc, additional

Published
2017
Full Text
View/download PDF

47. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study

Author

van Es, Nick, primary, Di Nisio, Marcello, additional, Cesarman, Gabriela, additional, Kleinjan, Ankie, additional, Otten, Hans-Martin, additional, Mahé, Isabelle, additional, Wilts, Ineke T., additional, Twint, Desirée C., additional, Porreca, Ettore, additional, Arrieta, Oscar, additional, Stépanian, Alain, additional, Smit, Kirsten, additional, De Tursi, Michele, additional, Bleker, Suzanne M., additional, Bossuyt, Patrick M., additional, Nieuwland, Rienk, additional, Kamphuisen, Pieter W., additional, and Büller, Harry R., additional

Published
2017
Full Text
View/download PDF

48. Screening for cancer in patients with unprovoked venous thromboembolism: protocol for a systematic review and individual patient data meta-analysis

Author

van Es, Nick, Le Gal, Grégoire, Otten, Hans-Martin, Robin, Philippe, Piccioli, Andrea, Lécumberri, Ramon, Jara Palomares, Luis, Religa, Piotr, Rieu, Viriginie, Rondina, Matthew T., Beckers, Mariëlle M., Prandoni, Paolo, Salaun, Pierre-Yves, Di Nisio, Marcello, Bossuyt, Patrick M., Büller, Harry R., Carrier, Marc, van Es, Nick, Le Gal, Grégoire, Otten, Hans-Martin, Robin, Philippe, Piccioli, Andrea, Lécumberri, Ramon, Jara Palomares, Luis, Religa, Piotr, Rieu, Viriginie, Rondina, Matthew T., Beckers, Mariëlle M., Prandoni, Paolo, Salaun, Pierre-Yves, Di Nisio, Marcello, Bossuyt, Patrick M., Büller, Harry R., and Carrier, Marc

Abstract

[Introduction] Occult cancer is present in 4%–9% of patients with unprovoked venous thromboembolism (VTE). Screening for cancer may be considered in these patients, with the aim to diagnose cancers in an early, potentially curable stage. Information is needed about the risk of occult cancer, overall and in specific subgroups, additional risk factors and on the performance of different screening strategies., [Methods and analysis] MEDLINE, Embase and CENTRAL databases were searched from November 2007 to January 2016 for prospective studies that had evaluated protocol-mandated screening for cancer in patients with unprovoked VTE and with at least 12 months’ follow-up. Two reviewers independently assessed articles for eligibility. Ten eligible studies were identified and individual patient data were obtained from each of them. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 tool . Generalised linear mixed-effects models was used to calculate estimates in a one-stage meta-analytic approach, overall and in a number of subgroups, including patients undergoing limited screening only, elderly patients, patients with previous VTE, smokers and patients using oestrogens., [Ethics and dissemination] Ethical approval is not required for this systematic review and individual patient data meta-analysis. Findings have been submitted for publication in peer-reviewed journals and presentations at national and international conferences to provide clinicians and other decision-makers with valid and precise risk estimates of occult cancer, overall and in specific clinical subgroups, with risk factors for occult cancer, with estimates of the diagnostic performance of limited screening and with an exploration of the benefit of extensive screening strategies.

Published
2017

49. Translating a clinical trial to daily practice: Outcome of palliative treatment in patients with advanced cholangiocarcinoma and gallbladder cancer in the Netherlands.

Author

Dierks, Joeri, primary, Coelen, Robert-Jan, additional, De Groot, Jan Willem, additional, Ten Tije, Albert J., additional, Meijer, Willem, additional, Pruijt, Hans, additional, Van Voorthuizen, Thymen, additional, van Spronsen, Dick Johan, additional, ten Oever, Diederik, additional, Smit, J. M., additional, Otten, Hans-Martin, additional, van Gulik, Thomas M, additional, Wilmink, Johanna, additional, and Klümpen, Heinz Josef, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results